AKR1D1 Antibody (C-2): sc-365932

AKR1D1 Antibody (C-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects AKR1D1 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). AKR1D1 (C-2) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. AKR1D1, also known as aldo-keto reductase family 1 member D1, Δ(4)-3-oxosteroid 5-β-reductase, or steroid 5-β-reductase, plays a crucial role in the metabolism of bile acid intermediates and steroid hormones by catalyzing the reduction of compounds with a Δ(4)-3-one structure to their 5-β reduced metabolites. This enzymatic activity is vital for maintaining hormonal balance and proper bile acid metabolism, which are essential for digestion and the regulation of various physiological processes. AKR1D1 is predominantly expressed in the liver, colon, and testis, and AKR1D1 substrates include testosterone, androstenedione, progesterone, and bile acid intermediates such as 7-α-hydroxy-4-cholesten-3-one. A deficiency in AKR1D1 can lead to significant hepatic dysfunction, highlighting the importance of this protein in metabolic pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AKR1D1 Antibody (C-2) References:

1. Assignment of steroid 5beta-reductase (SRD5B1) and its pseudogene (SRD5BP1) to human chromosome bands 7q32-->q33 and 1q23-->q25, respectively, by in situ hybridization.  |  Charbonneau, A. and Luu-The, V. 1999. Cytogenet Cell Genet. 84: 105-6. PMID: 10343119
2. Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme.  |  Charbonneau, A. and The, VL. 2001. Biochim Biophys Acta. 1517: 228-35. PMID: 11342103
3. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.  |  Lemonde, HA., et al. 2003. Gut. 52: 1494-9. PMID: 12970144
4. SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect.  |  Gonzales, E., et al. 2004. J Hepatol. 40: 716-8. PMID: 15030995
5. 5 Beta-dihydroprogesterone and steroid 5 beta-reductase decrease in association with human parturition at term.  |  Sheehan, PM., et al. 2005. Mol Hum Reprod. 11: 495-501. PMID: 16123077
6. Aldo-keto reductases and bioactivation/detoxication.  |  Jin, Y. and Penning, TM. 2007. Annu Rev Pharmacol Toxicol. 47: 263-92. PMID: 16970545
7. AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.  |  Nikolaou, N., et al. 2019. Metabolism. 99: 67-80. PMID: 31330134
8. AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.  |  Gathercole, LL., et al. 2022. J Endocrinol. 253: 97-113. PMID: 35318963
9. Recurrent AKR1D1 c.580-13T>A Variant: A Cause of Δ4-3-Oxosteroid-5β-Reductase Deficiency.  |  Zhao, J., et al. 2023. J Mol Diagn. 25: 227-233. PMID: 36739965
10. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme.  |  Kondo, KH., et al. 1994. Eur J Biochem. 219: 357-63. PMID: 7508385
11. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.  |  Clayton, PT., et al. 1996. Gut. 38: 623-8. PMID: 8707100
12. Gene analysis in delta 4-3-oxosteroid 5 beta-reductase deficiency.  |  Sumazaki, R., et al. 1997. Lancet. 349: 329. PMID: 9024384

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-AKR1D1 Antibody (C-2) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-AKR1D1 Antibody (C-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

AKR1D1 Antibody (C-2) Specifications

Alternate Product Name: AKR1D1

Product Clone Name: C-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 13-37

Epitope Target: AKR1D1

Epitope Species: human

Product Reactivity/Detection: AKR1D1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine and bovine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for AKR1D1 Antibody (C-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin